A federal appeals court denied a bid by a pharmaceutical industry trade group to block a closely watched ... something else of value to an erstwhile generic rival, which agrees to delay launching ...

Celgene contends that a generic version would infringe 10 patents and is seeking a ruling that would block approval until all expire. The patents expire from 2016 through 2026, according to ...

The Federal Circuit on Tuesday rejected Novartis' request for a mandate that would immediately block the generic. Novartis separately sued the U.S. Food and Drug Administration in Washington ...